KalVista Pharmaceuticals (KALV) Net Margin (2014 - 2025)

KalVista Pharmaceuticals (KALV) reported Net Margin of 120.28% for Q3 2025, up 74.67% sequentially from 474.85% in Q2 2025.

KalVista Pharmaceuticals (KALV) Net Margin (2014 - 2025) Analysis & Trends

KalVista Pharmaceuticals (KALV) has 8 years of Net Margin data on file, last reported at 120.28% in Q3 2025.

  • For the quarter ending Q3 2025, Net Margin changed N/A year-over-year to 120.28%; the trailing twelve-month figure through Jul 2025 stood at 253.66% (up 59510.0% YoY), and the FY2025 full-year result was 1667.75%, down 156242.0% from the prior year.
  • Net Margin advanced to 120.28% in Q3 2025, from 474.85% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 120.28% in Q3 2025 to a low of 474.85% in Q2 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Margin (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 15.02%
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 34.53%
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn 20.17%
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn 30.33%
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 KalVista Pharmaceuticals 1.36 Bn 1.36 Bn 49.41 Mn -120.28%

Historic Data

Download Data
DateValue
Jul 31, 2025 -120.28%
Apr 30, 2025 -474.85%
Apr 30, 2020 -196.78%
Jan 31, 2020 -920.48%
Oct 31, 2019 -275.05%
Jul 31, 2019 -288.25%
Apr 30, 2019 -378.09%
Jan 31, 2019 -161.03%
Oct 31, 2018 -89.65%
Jul 31, 2018 -194.92%
Apr 30, 2018 -13.57%
Jan 31, 2018 -224.54%
Oct 31, 2017 -442.41%
Jul 31, 2017 -5,133.33%
Apr 30, 2017 -3,685.96%
Jan 31, 2017 -3,167.34%
Oct 31, 2016 -2,152.79%
Jul 31, 2016 -458.97%
Mar 31, 2016 -102,342.86%
Dec 31, 2015 -80,800.00%